Subtypes of basal cell carcinoma, the most common type of skin cancer, may differ in appearance, aggressiveness, treatment options, and who’s likely to develop them. Basal cell carcinoma (BCC) is the ...

In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC). At 5 years ...

Basal cell carcinoma is the most common skin cancer, often caused by UV exposure, and originates in the epidermis's basal cells. Diagnosis involves clinical examination and biopsy to confirm BCC and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Five years after treatment, results showed a freedom ...

Please provide your email address to receive an email when new articles are posted on . AIV001 is a pan-tyrosine kinase inhibitor for the nonsurgical treatment of mixed basal cell carcinomas. Injected ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Basal cell carcinoma and squamous cell carcinoma are the two most common types of non-melanoma skin cancer. These cancers begin in different layers of the skin. Squamous cell carcinoma starts in the ...

Medicus Pharma reports over 50% patient enrollment in Phase 2 study for basal cell carcinoma treatment, aiming for FDA fast-track approval. Medicus Pharma Ltd. announced that over 50% of the 60 ...

Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...

WASHINGTON, DC — A woman in her late 80s with mild dementia was recently referred to Vishal A. Patel, MD, director of cutaneous oncology at the George Washington (GW) Cancer Center, director of ...

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, ...